A Phase Ib Dose Escalation Study of MK-4827 in Combination With Pegylated Liposomal Doxorubicin (Doxil or Caelyx) in Patients With Advanced Solid Tumors With a Cohort Expansion in Patients With Platinum Resistant/Refractory High Grade Serous Ovarian Cancer.

Trial Profile

A Phase Ib Dose Escalation Study of MK-4827 in Combination With Pegylated Liposomal Doxorubicin (Doxil or Caelyx) in Patients With Advanced Solid Tumors With a Cohort Expansion in Patients With Platinum Resistant/Refractory High Grade Serous Ovarian Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2016

At a glance

  • Drugs Niraparib (Primary) ; Doxorubicin liposomal
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TESARO
  • Most Recent Events

    • 30 Sep 2011 Planned End Date changed from 1 Jan 2012 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 30 Sep 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 07 Sep 2011 Planned end date changed from 1 Sep 2011 to 1 Jan 2012 as reportrd by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top